Nintedanib treatment for bleomycin-induced lung injury - First report

Although the antineoplastic agent bleomycin is known for more than 50 years, its exact pharmacological and side-effect mechanisms remain incompletely understood. The major limitation of bleomycin therapy is the risk of pulmonary toxicity which can be diverse, and potentially fatal in 10% of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Rnjak, Dina, Batarilo Hađar, Martina, Pelicarić, Dubravka, Vukić, Tea, Janković Makek, Mateja, Samaržija, Miroslav, Hećimović, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562906/
https://www.ncbi.nlm.nih.gov/pubmed/37822763
http://dx.doi.org/10.1016/j.rmcr.2023.101921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562906/
https://www.ncbi.nlm.nih.gov/pubmed/37822763
http://dx.doi.org/10.1016/j.rmcr.2023.101921

Ejemplares similares